Indaptus Therapeutics appoints Mark J. Gilbert to Board, replacing Hoonmo Lee

Indaptus Therapeutics, Inc.

Hoonmo Lee resigned from the Board effective Nov. 29, 2021, with no disagreement.
Board elected Mark J. Gilbert, M.D. as Class I director, term until 2022 annual meeting.
Dr. Gilbert is EVP of R&D at Acepodia, former CMO of Juno Therapeutics.
Dr. Gilbert granted option to purchase 20,000 shares at $5.35/share, vesting in 1 year.
Eligible for annual retainer of $50,000 and additional option grants at each annual meeting.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Hoonmo Lee

Director

INDP · Indaptus Therapeutics, Inc.

Effective: 2021-11-29
Successor: Mark J. Gilbert
Filed: December 2, 2021, 6:59 PM ET

On November 29, 2021, Mr. Hoonmo Lee tendered his resignation from the Board of Directors (the “Board”) of Indaptus Therapeutics, Inc. (the “Company”), and from all committees of the Board.

Appointed

Mark J. Gilbert

Director

INDP · Indaptus Therapeutics, Inc.

Effective: 2021-11-29
Filed: December 2, 2021, 6:59 PM ET

On the same day, the Board elected Mark J. Gilbert, M.D. as a member of the Board, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Hoonmo Lee resigned as Director at Indaptus Therapeutics, Inc..

Action: resigned
Role: Director

Exact text from the filing

On November 29, 2021, Mr. Hoonmo Lee tendered his resignation from the Board of Directors (the “Board”) of Indaptus Therapeutics, Inc. (the “Company”), and from all committees of the Board.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Mark J. Gilbert was elected as Director at Indaptus Therapeutics, Inc..

Action: elected
Role: Director

Exact text from the filing

On the same day, the Board elected Mark J. Gilbert, M.D. as a member of the Board, effective immediately.

View on SEC.gov

Indaptus Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-21-030260

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.